Prostasin regulates PD-L1 expression in human lung cancer cells.


Journal

Bioscience reports
ISSN: 1573-4935
Titre abrégé: Biosci Rep
Pays: England
ID NLM: 8102797

Informations de publication

Date de publication:
30 07 2021
Historique:
received: 05 06 2021
revised: 18 06 2021
accepted: 25 06 2021
entrez: 9 7 2021
pubmed: 10 7 2021
medline: 1 2 2022
Statut: ppublish

Résumé

The serine protease prostasin is a negative regulator of lipopolysaccharide-induced inflammation and has a role in the regulation of cellular immunity. Prostasin expression in cancer cells inhibits migration and metastasis, and reduces epithelial-mesenchymal transition. Programmed death-ligand 1 (PD-L1) is a negative regulator of the immune response and its expression in cancer cells interferes with immune surveillance. The aim of the present study was to investigate if prostasin regulates PD-L1 expression. We established sublines overexpressing various forms of prostasin as well as a subline deficient for the prostasin gene from the Calu-3 human lung cancer cells. We report here that PD-L1 expression induced by interferon-γ (IFNγ) is further enhanced in cells overexpressing the wildtype membrane-anchored prostasin. The PD-L1 protein was localized on the cell surface and released into the culture medium in extracellular vesicles (EVs) with the protease-active prostasin. The epidermal growth factor-epidermal growth factor receptor (EGF-EGFR), protein kinase C (PKC), and mitogen-activated protein kinase (MAPK) participated in the prostasin-mediated up-regulation of PD-L1 expression. A Gene Set Enrichment Analysis (GSEA) of patient lung tumors in The Cancer Genome Atlas (TCGA) database revealed that prostasin and PD-L1 regulate common signaling pathways during tumorigenesis and tumor progression.

Identifiants

pubmed: 34240739
pii: 229226
doi: 10.1042/BSR20211370
pmc: PMC8273379
pii:
doi:

Substances chimiques

B7-H1 Antigen 0
CD274 protein, human 0
Epidermal Growth Factor 62229-50-9
Interferon-gamma 82115-62-6
EGFR protein, human EC 2.7.10.1
ErbB Receptors EC 2.7.10.1
Protein Kinase C EC 2.7.11.13
Mitogen-Activated Protein Kinases EC 2.7.11.24
Serine Endopeptidases EC 3.4.21.-
prostasin EC 3.4.21.-

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2021 The Author(s).

Références

Biomolecules. 2020 Sep 07;10(9):
pubmed: 32906765
N Engl J Med. 2016 Sep 22;375(12):1109-12
pubmed: 27653561
Nat Commun. 2014 Mar 11;5:3428
pubmed: 24614850
Am J Physiol Renal Physiol. 2006 Sep;291(3):F567-77
pubmed: 16638913
PLoS One. 2014 Sep 02;9(9):e106397
pubmed: 25181531
Cell Physiol Biochem. 2017;42(1):281-294
pubmed: 28535513
J Biol Chem. 2001 Jun 15;276(24):21434-42
pubmed: 11274175
Cancer Discov. 2013 Dec;3(12):1355-63
pubmed: 24078774
BMC Cancer. 2015 Dec 29;15:1025
pubmed: 26715240
Genomics. 1994 Oct;23(3):704-6
pubmed: 7851902
Mol Cancer Ther. 2005 May;4(5):726-32
pubmed: 15897236
Prostate. 2004 Apr 1;59(1):1-12
pubmed: 14991861
Cardiovasc Res. 2003 Oct 1;59(4):934-44
pubmed: 14553833
Anticancer Res. 2007 May-Jun;27(3A):1285-94
pubmed: 17593621
Biochim Biophys Acta. 2008 May;1783(5):896-903
pubmed: 18054338
Cell Immunol. 2018 Sep;331:121-129
pubmed: 29935764
J Biol Chem. 2002 Mar 1;277(9):7118-26
pubmed: 11751911
Hum Reprod. 2010 Mar;25(3):623-32
pubmed: 20089521
EMBO J. 1992 Nov;11(11):3887-95
pubmed: 1396582
Eur J Cancer. 2001 Sep;37 Suppl 4:S16-22
pubmed: 11597400
J Hematol Oncol. 2017 Apr 24;10(1):87
pubmed: 28434399
Nature. 2017 Sep 7;549(7670):106-110
pubmed: 28813410
Nat Cell Biol. 2018 Mar;20(3):332-343
pubmed: 29459780
BMC Cancer. 2009 Oct 22;9:377
pubmed: 19849847
J Immunother Cancer. 2019 Nov 15;7(1):305
pubmed: 31730010
Bioinformatics. 2014 Feb 15;30(4):523-30
pubmed: 24336805
Histochem Cell Biol. 2009 Dec;132(6):639-46
pubmed: 19847458
Nature. 2018 Aug;560(7718):382-386
pubmed: 30089911
Sci Rep. 2016 Mar 02;6:22519
pubmed: 26931825
Cells. 2019 Jul 15;8(7):
pubmed: 31311206
J Biol Chem. 1994 Jul 22;269(29):18843-8
pubmed: 8034638
J Biomed Sci. 2020 Jul 3;27(1):77
pubmed: 32620165
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
Biochem Soc Trans. 2014 Feb;42(1):59-62
pubmed: 24450628
Sci Rep. 2017 May 12;7(1):1878
pubmed: 28500324
Anal Biochem. 1995 Jan 1;224(1):166-72
pubmed: 7710065
Prostate. 2001 Jul 1;48(2):93-103
pubmed: 11433419
J Biol Chem. 1995 Jun 2;270(22):13483-9
pubmed: 7768952
Sci Rep. 2019 Nov 5;9(1):16039
pubmed: 31690751
Onco Targets Ther. 2014 Jun 12;7:1015-23
pubmed: 24959088
Analyst. 2016 Aug 07;141(15):4640-6
pubmed: 27229443
J Clin Invest. 2015 Sep;125(9):3384-91
pubmed: 26325035
Proc Natl Acad Sci U S A. 2016 Feb 23;113(8):E968-77
pubmed: 26858453
Drugs Today (Barc). 2006 Jul;42(7):441-53
pubmed: 16894399
Nat Commun. 2016 Aug 30;7:12632
pubmed: 27572267
Front Med (Lausanne). 2018 Dec 12;5:351
pubmed: 30631766
Cytokine Growth Factor Rev. 2008 Oct-Dec;19(5-6):383-94
pubmed: 18929502
Blood. 2003 Dec 15;102(13):4336-44
pubmed: 12881314
Proc Natl Acad Sci U S A. 2003 Apr 29;100(9):5336-41
pubmed: 12697896
Nat Med. 1999 Dec;5(12):1365-9
pubmed: 10581077
Cell Rep. 2018 Jul 17;24(3):630-641
pubmed: 30021161
Cell Rep. 2017 May 9;19(6):1189-1201
pubmed: 28494868
Int J Cancer. 2002 Jan 20;97(3):323-9
pubmed: 11774283
J Pathol. 2019 Sep;249(1):52-64
pubmed: 30972766
J Thorac Oncol. 2016 Jul;11(7):976-88
pubmed: 26944305
J Exp Med. 2016 Dec 12;213(13):2835-2840
pubmed: 27903604
Sci Adv. 2018 Mar 07;4(3):eaar2766
pubmed: 29532035
Nat Immunol. 2007 Mar;8(3):239-45
pubmed: 17304234
Mol Vis. 2015 Aug 21;21:901-10
pubmed: 26321864
Prostate. 2009 Dec 1;69(16):1790-801
pubmed: 19670249
EMBO J. 2001 Apr 2;20(7):1583-92
pubmed: 11285223
Proc Natl Acad Sci U S A. 2011 Sep 13;108(37):15336-41
pubmed: 21873242
Nature. 2017 Sep 7;549(7670):101-105
pubmed: 28813417
J Immunother. 2007 Apr;30(3):251-60
pubmed: 17414316

Auteurs

Li-Mei Chen (LM)

Division of Cancer Research, Burnett School of Biomedical Sciences, University of Central Florida College of Medicine, Orlando, FL, U.S.A.

Julius C Chai (JC)

Division of Cancer Research, Burnett School of Biomedical Sciences, University of Central Florida College of Medicine, Orlando, FL, U.S.A.

Bin Liu (B)

Department of Epigenetics and Molecular Carcinogenesis, Division of Basic Science Research, The University of Texas MD Anderson Cancer Center, Smithville, TX, U.S.A.

Tara M Strutt (TM)

Division of Immunity and Pathogenesis, Burnett School of Biomedical Sciences, University of Central Florida College of Medicine, Orlando, FL, U.S.A.

K Kai McKinstry (KK)

Division of Immunity and Pathogenesis, Burnett School of Biomedical Sciences, University of Central Florida College of Medicine, Orlando, FL, U.S.A.

Karl X Chai (KX)

Division of Cancer Research, Burnett School of Biomedical Sciences, University of Central Florida College of Medicine, Orlando, FL, U.S.A.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH